Cargando…
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
SIMPLE SUMMARY: CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are the established first-line treatment for metastatic and advanced hormone receptor-positive breast cancer (mBC). Recently, there has been an expansion in available next lines of therapy; however, optimal sequencing remains unclear...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046856/ https://www.ncbi.nlm.nih.gov/pubmed/36980743 http://dx.doi.org/10.3390/cancers15061855 |